December 17, 2025 — Galux, a South Korean biotech company focused on AI-driven protein therapeutics, has entered a research collaboration with Boehringer Ingelheim to explore the use of artificial intelligence in precision protein design for therapeutic development.
The collaboration aims to evaluate how AI can be applied to design protein molecules with specific properties that address highly targeted scientific and translational needs, where traditional methods may face limitations.
“Through this agreement, we aim to explore how AI protein design can address highly specific scientific and translational needs—challenges that often require precise and tailored molecular solutions,” said Chaok Seok, CEO of Galux. “It’s about demonstrating that AI can move beyond prediction to purposeful molecular design, creating proteins that meet clearly defined research and therapeutic goals.”
The initial phase of the collaboration will focus on validating the feasibility and potential of AI-driven protein design in selected cases, laying the groundwork for broader research initiatives between the two companies.
“At Galux, we believe the future of therapeutics lies in precise design. This collaboration is an important step toward realizing that vision, combining the capabilities of AI with biomedical expertise to unlock new possibilities in drug development,” added Seok.
The partnership reflects a growing trend in the pharmaceutical and biotechnology industry to integrate artificial intelligence into drug discovery and development, particularly in areas requiring highly specific molecular solutions that were previously challenging to achieve.
By
